121 related articles for article (PubMed ID: 7775127)
1. Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity.
Díaz-Rubio E; Martín M; López-Vega JM; Casado A; Benavides A
Invest New Drugs; 1994; 12(4):277-81. PubMed ID: 7775127
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
Taylor SA; Rankin C; Townsend JJ; Craig JB; Vance RB; Solank DL; Brown TD; Jaeckle K;
Invest New Drugs; 2002 Feb; 20(1):113-5. PubMed ID: 12003186
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of mitonafide in solid tumors.
Llombart M; Poveda A; Forner E; Fernández-Martos C; Gaspar C; Muñoz M; Olmos T; Ruiz A; Soriano V; Benavides A
Invest New Drugs; 1992 Aug; 10(3):177-81. PubMed ID: 1428727
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of mitonafide in non-small cell lung cancer (NSCLC).
Casado A; Rosell R; García-Gómez R; Díaz-Rubio E; Pérez-Manga G; Font A; Benavides A; Martín M
Invest New Drugs; 1996; 14(4):415-7. PubMed ID: 9157079
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.
Rosell R; Carles J; Abad A; Ribelles N; Barnadas A; Benavides A; Martin M
Invest New Drugs; 1992 Aug; 10(3):171-5. PubMed ID: 1330970
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of Mitonafide in advanced and relapsed colorectal cancer.
Abad A; Grávalos C; Font A; Molina F; Díaz-Puente MT; Fabregat X; Benavides A; Martín M
Invest New Drugs; 1996; 14(2):223-5. PubMed ID: 8913845
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
8. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of amonafide in advanced and recurrent sarcoma patients.
Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ
Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
Marshall ME; Blumenstein B; Crawford ED; Thompson IM; Craig JB; Eisenberger M; Ahmann F
Am J Clin Oncol; 1994 Dec; 17(6):514-5. PubMed ID: 7977172
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
12. An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
Leaf AN; Neuberg D; Schwartz EL; Wadler S; Ritch PS; Dutcher JP; Adams GL
Invest New Drugs; 1997; 15(2):165-72. PubMed ID: 9220297
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
Mullane MR; Schilsky RL; Carroll RB; Wade JL; Kilton LJ; Blough RR; Bauman A; French SL; Benson AB
Invest New Drugs; 1994; 12(3):267-70. PubMed ID: 7896548
[TBL] [Abstract][Full Text] [Related]
14. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
Brown TD; Ettinger DS; Donehower RC
J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
Asbury R; Blessing JA; Reid GC; McGuire WP
Am J Clin Oncol; 1998 Aug; 21(4):406-7. PubMed ID: 9708643
[TBL] [Abstract][Full Text] [Related]
18. Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.
Asbury R; Blessing JA; Buller R; Malfetano JH; Walker J; Sevin BU
Am J Clin Oncol; 1998 Apr; 21(2):145-6. PubMed ID: 9537200
[TBL] [Abstract][Full Text] [Related]
19. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
[TBL] [Abstract][Full Text] [Related]
20. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
